Prota Therapeutics
PrivateLast Round
Series A
Extension
Jan 16, 2024
Total Funding Raised
$43.48M
Company Overview
Prota Therapeutics operates in Healthcare & Life Sciences and is based in Melbourne. Its latest recorded funding round was a Series A Extension round in January 2024.
Prota Therapeutics is a biotechnology company that develops and commercializes oral immunotherapy treatments for food allergies.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Clinical Trials
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Prota Therapeutics Comparables
Compare Prota Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Aravax | 87% | |
| Intrommune Therapeutics | 84% | |
| Camallergy | 83% |
For institutional investors. Book with your work email.
Prota Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series A Extension | Jan 16, 2024 | ||||
| Series A | May 27, 2017 | ||||
| Series A | Sep 1, 2016 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Prota Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| OneVentures | Series A Extension, Series A |
| SPRIM Global Investments | Series A Extension |
| SPRIM Global Investments | Series A Extension |
Market signals
Structured signals derived from secondary market and firmographic data.
- Sep 17, 2025
Investigational peanut allergy therapy PRT120 mentioned in award announcement.
- Sep 17, 2025
Awarded for joint clinical research with Murdoch Children's Research Institute.
For institutional investors. Book with your work email.
Prota Therapeutics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Prota Therapeutics's valuation, stock price, and market status.
Is Prota Therapeutics a public or private company?
Prota Therapeutics is a private company.
What is the current stock price of Prota Therapeutics?
Prota Therapeutics is a private company, so its shares have no public market price. Caplight tracks Prota Therapeutics's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Prota Therapeutics worth (valuation)?
Valuation information for Prota Therapeutics is not publicly available.
Can I buy Prota Therapeutics stock?
Prota Therapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Prota Therapeutics's last funding round?
Prota Therapeutics's most recent funding round was Series A Extension on January 16, 2024.
Who are the main investors in Prota Therapeutics?
Key investors in Prota Therapeutics include OneVentures, SPRIM Global Investments, SPRIM Global Investments.
Will Prota Therapeutics IPO soon?
No public IPO plans have been announced for Prota Therapeutics.
How can I track Prota Therapeutics secondary market activity?
Caplight tracks bids, offers, and trades in Prota Therapeutics's shares on secondary markets.